Allergen Specific Sublingual Immunotherapy (Acarizax and Grazax) In Paediatrics(330 KB) - Shared care agreement
Date added: 3rd Oct 2024
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena®) (UPDATED) | Yellow | Maintenance treatment of schizophrenia in patients currently stabilised on oral aripiprazole |
See the LLR Antipsychotic Prescribing Guide 2 strengths available: 400mg (each month) and 960mg (every 2 months) |
| Aspirin | Yellow | Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics |
*on advice of clinical genetics Patient weight <75kg: 150mg daily Patient weight >75kg: 300mg daily |
| ATOMOXETINE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents
|
| BETULA VERRUCOSA ALLERGEN EXTRACT (Itulazax®) (NEW) | Red | Moderate to severe allergic rhinitis/conjunctivitis caused by Birch pollen | |
| Bismuth, Metronidazole & Tetracycline ( Pylera) (NEW) | Green | Eradication of H. Pylori for patients with penicillin allergy already exposed to clarithromycin |
Use in line with local antimicrobial guidelines. |
| Denosumab (Xgeva) | Red | Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min) | |
| DERMATOPHAGOIDES PTERONYSSINUS ALLERGEN EXTRACT (Acarizax®) (UPDATED) | Orange | Immunotherapy treatment for house dust mite and allergic rhinitis in paediatrics. | |
| DEXAMFETAMINE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents |
| DexcomONE + | Yellow | Diabetes glucose monitoring for those included on the LLRAPC position statement |
Update September 2024: DexcomONE + is now available; all new patients must be started on the updated device. DexcomONE is due to be discontinued early 2025, exact date to be confirmed. |
| Estradiol & Medroxyprogesterone (Tridestra) (NEW) | Green | Hormone replacement therapy | |
| Estradiol & Norethisterone (Trisequens) (NEW) | Green | Hormone replacement therapy | |
| ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) (UPDATED) | Yellow | For treating moderate to severe symptoms of uterine fibroids in adults of reproductive age. |
Treatment for 6-12 months at the direction of specialist team. In line with NICE TA832 |
| Finerenone | Green | Stage 3 and 4 chronic kidney disease associated with diabetes |
For treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults in line with NICE TA877. Use in line with the CKD Pathway. |
| Freestyle Libre 2 Plus | Yellow | Continuous glucose monitoring (CGM) for those included on the LLRAPC position statement. |
Update September 2024: Freestyle Libre 2 Plus is now available; all new patients must be started on the updated device. Freestyle Libre 2 is due to be discontinued early 2025, exact date to be confirmed. |
| GRASS POLLEN ALLERGEN EXTRACT sublingual (Grazax®) (UPDATED) | Orange | Grass pollen allergies | |
| GUANFACINE (UPDATED) | Orange | ADHD - Adult |
Adult Full SCA and Request Form |
| Lebrikizumab (NEW) | Red | For treating moderate to severe atopic dermatitis in people 12 years and over | |
| LEFLUNOMIDE (UPDATED) | Orange | Rheumatological disease | |
| LISDEXAMFETAMINE DIMESYLATE (UPDATED) | Orange | ADHD when response to methylphenidate is inadequate |
Adults Children and adolescents |
| METHOTREXATE Oral (UPDATED) | Orange | Rheumatological disease |
Full SCA Request form Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied. |
| METHYLPHENIDATE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care. |
| Nephrotrans (UPDATED) | Yellow | metabolic acidosis in chronic kidney disease |
Treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment only (limited use as a 2nd line option for patients who cannot tolerate the standard capsules e.g. due to bloating).’ To be initiated by renal team only. |
| Tenecteplase (NEW) | Red | For treating acute ischaemic stroke | |
| Varenicline Tartrate (Champix) | Grey | Smoking cessation in adults |
Other Updates on this Website
Recent documents from LLR APC and TAS
Dexamfetamine (Adults)(405 KB) - Shared care agreement
Date added: 3rd Oct 2024
Atomoxetine (Adults)(401 KB) - Shared care agreement
Date added: 3rd Oct 2024
Lisdexamfetamine (Adults)(475 KB) - Shared care agreement
Date added: 3rd Oct 2024
Methylphenidate (Adults)(589 KB) - Shared care agreement
Date added: 3rd Oct 2024
Guanfacine (Adults)(463 KB) - Shared care agreement
Date added: 3rd Oct 2024
LLR APC & TAS Meeting Dates & Cut Offs 2025(545 KB) - TAS
Date added: 3rd Oct 2024
LLRAPC Meeting Minutes September 2024(862 KB) - LMSG/LLR APC minutes
Date added: 2nd Oct 2024
Urgent Palliative Medication Delivery Service (Prescribing, Authorisation, Administration and Accessing Urgent Supply)(442 KB) - Guidelines
Date added: 27th Sep 2024
Ratification Process & Structure of the Medicines Code(207 KB) - Guidelines
Version 2.0 Updated October 2024
Date added: 11th Oct 2023
Antipsychotic Prescribing Guide for Primary Care(939 KB) - Guidelines
Version 1.2 Uploaded September 2024
Date added: 29th Jul 2022
Menopause and HRT(1 MB) - Guidelines
Version 1.1 Uploaded September 2024
Date added: 15th Jun 2022
Fixed Dose Combination Medicines – Position Statement(292 KB) - Guidelines
Version 3 Uploaded October 2024
Date added: 3rd May 2017
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more